Focused On-demand Libraries - Receptor.AI Collaboration


Explore the Potential with AI-Driven Innovation

Our detailed focused library is generated on demand with advanced virtual screening and parameter assessment technology powered by the Receptor.AI drug discovery platform. This method surpasses traditional approaches, delivering compounds of better quality with enhanced activity, selectivity, and safety.


The compounds are cherry-picked from the vast virtual chemical space of over 60B molecules. The synthesis and delivery of compounds is facilitated by Reaxense.


The library includes a list of the most promising modulators annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Also, each compound is presented with its optimal docking poses, affinity scores, and activity scores, providing a comprehensive overview.


Our high-tech, dedicated method is applied to construct targeted libraries.


 

Fig. 1. The screening workflow of Receptor.AI

By deploying molecular simulations, our approach comprehensively covers a broad array of proteins, tracking their flexibility and dynamics individually and within complexes. Ensemble virtual screening is utilised to take into account conformational dynamics, identifying pivotal binding sites located within functional regions and at allosteric locations. This thorough exploration ensures that every conceivable mechanism of action is considered, aiming to identify new therapeutic targets and advance lead compounds throughout a vast spectrum of biological functions.


Key features that set our library apart include:


  • The Receptor.AI platform integrates extensive information about the target protein, such as historical experiments, academic research, known ligands, and structural insights, thereby increasing the likelihood of identifying highly relevant compounds.

  • The platform’s sophisticated molecular simulations are designed to discover potential binding sites, ensuring that our focused library is optimal for the discovery of allosteric inhibitors and binders for cryptic pockets.

  • With over 50 customisable AI models, verified through extensive testing in commercial drug discovery and research, Receptor.AI is efficient, reliable, and precise. These models are essential in the production of our focused libraries.

  • Receptor.AI not only produces focused libraries but also provides full services and solutions at every stage of preclinical drug discovery, with a success-based pricing structure that aligns our interests with the success of your project.


PARTNER
Receptor.AI
 
UPACC
P13535

UPID:
MYH8_HUMAN

ALTERNATIVE NAMES:
Myosin heavy chain 8; Myosin heavy chain, skeletal muscle, perinatal

ALTERNATIVE UPACC:
P13535; Q14910

BACKGROUND:
The protein Myosin-8, with alternative names Myosin heavy chain 8 and Myosin heavy chain, skeletal muscle, perinatal, is integral to muscle contraction. Its pivotal role in this essential physiological process underscores its significance in the musculoskeletal system.

THERAPEUTIC SIGNIFICANCE:
Given Myosin-8's involvement in Carney complex variant and Arthrogryposis, distal, 7, exploring its functions could lead to novel therapeutic approaches. The connection between Myosin-8 and these diseases highlights the importance of research into its biological roles and disease associations.

Looking for more information on this library or underlying technology? Fill out the form below and we will be in touch with all the details you need.


Error: Google reCAPTCHA script is not loaded. Make sure your browser is not blocking it or contact the site administrator.